JPRN-jRCT2080221521UnknownPhase 1
A Phase I, Randomized, Double-Blind, Placebo-Controlled Trial of Single and Multiple Doses of TAS-114 in Healthy Adult Male Subjects
Conditions
Trial Snapshot
- Phase
- Phase 1
- Enrollment
- 35
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 20age old to <= 39age old (—)
- Sex
- Male
Inclusion Criteria
- •Healthy male subject who have given written informed consent
- •- Subject's age of twenty years old or more and less than forty years old
- •- Subject's weight of 50.0kg or more and BMI (Body Mass Index) of 18.0-25.0kg/m2
Exclusion Criteria
- •- Subject with a history or concurrent status of allergic reaction
- •- Subject with a history or concurrent status of alcoholic or drug addiction
- •- Subject who is not willing to stop smoking during hospitalization
- •- Subject who recieved other investigational drug within 180 days before receiving the study drug
Investigators
Similar Trials
Not yet recruiting
Phase 1
A Phase I Study of AV-1959R, an Amyloid Beta Vaccine in Healthy ParticipantsNeurological - Alzheimer's diseaseAlzheimer's DiseaseACTRN12624000737538Arvax Pty Ltd16
Not yet recruiting
Phase 1
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of ACT004 in Healthy Adult SubjectsACTRN12622001507774Accendatech AU Pty Ltd.82
Completed
Not Applicable
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study To Assess The Safety, Tolerability, Pharmacokinetics Of Two Monoclonal Antibodies In Healthy VolunteersNL-OMON51340Aerium Therapeutics80
Recruiting
Phase 1
A Study to Evaluate the Safety of BW-00163 in Healthy and Mild Hypertension SubjectsCardiovascular - HypertensionHypertensionACTRN12623000023651ARGO BIOPHARMA AUSTRALIA PTY LTD56
Recruiting
Phase 1
A first in human study to Evaluate the Safety and Tolerability of OLX75016 for treatment of nonalcoholic steatohepatitis (NASH) and liver fibrosis.(NAFLD) to steatohepatitis (NASH)fibrosisOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonCirrhosisACTRN12624000023550OliX AU Pty Ltd70